Dr. Gendelman's Laboratory

Research Goals
Collaborators
Funding
Techniques used in the lab
Personnel
Return to Dr. Gendelman's home page
Dr. Gendelman's biographical information


Research Goals

The current and longer-range goals of the laboratory are to develop antiretroviral, immune transformative, gene editing and theranostic agents to improve the diagnosis, treatment and “cure” options for viral and neurodegenerative diseases.

The laboratory initiative is a consortium of research collaborators divided into specific programs, each co-led by established investigators with specific expertise in immunology, molecular biology, infectious disease, proteomics, physiology, chemistry and pathogenesis. These provide the student and research fellow an interdisciplinary research experience.

First, studies revolving around the development of cell-based long-acting drug delivery. Nanotoxicology studies involve the studies of the regulation of leukocyte entry into peripheral and neural tissues with a focus on restoring nervous system homeostasis and glial immunity. This is seen during neurodegenerative diseases and include studies of Parkinson’s and Alzheimer’s diseases. Those agents that are being developed include, but are not limited to, antiviral, neuroprotective, and anti-inflammatory drugs.

Second, drug testing of both neuroprotective and neuroregenerative medicines used in combination with diagnostics are being developed in disease-relevant animal models for disease. This program is part of national grant efforts that involve scientists at the University of Nebraska Medical Center and Moderna, Calibr, Exavir and Partner Biotechnology Companies. The focus is to perform translational and clinical research.

Third, transcriptomic, proteomic and metabolomic approaches for biomarker discovery are linked to studies of cell-cell interactions for disease. This is part of a broader initiative of how transformative medicines can suppress, eliminate and or transform viral replication and brain immune dysregulation.

Fourth, neuroimmunologic approaches that induce protective immunity are being pursued in animal models of neurodegenerative diseases. The laboratory has developed a unique immunoregulatory approach that uses T cell sources for brain repair to combat neurodegeneration.

top of page


Collaborators

Siddappa Byrareddy, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Prasanta Dash, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Paul L. Domanico, Clinton Health Access Initiative, Research Triangle Park, NC
Benson Edagwa, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Santhi Gorantla, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Bhavesh Kevadiya, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Kamel Khalili, Lewis Katz School of Medicine at Temple University, Philadelphia, PA
Yutong Liu, Radiology, UNMC, Omaha, NE
JoEllyn McMillan, Pharmacology and Experimental Neuroscience, UNMC Omaha, NE
R. Lee Mosley, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
Larisa Poluektova, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE
David Volsky, Icahn School of Medicine at Mount Sinai, New York, NY
Xinglong Wang, Pharmacology and Experimental Neuroscience, UNMC, Omaha, NE

top of page


Funding

Neuroprotective Immunity and HIV Dementia
MPI: Gendelman, H.E. and Mosley, R.L.
NIH/NINDS NS034239
This proposal will determine cell responses in macrophages following HIV-1 infection and engagement with T cells and T cell subsets. Macrophage functions including phagocytosis, antigen presentation, intracellular killing and effector cell responses and their modulation by T cells is a focus for this work. Signal transduction pathways and mechanisms for virus-induced neurotoxicity or neuroprotection will be developed.

LASER ART for PrEP
MPI: Gendelman, H.E. and Edagwa, B.
DHHS/NIH 1R01AI158160-01A1
LASER ART for PrEP is designed to develop, characterize, test and produce long acting antiretroviral therapy for the prevention of HIV/AIDS. The work is based on the notion that a year injectable can be administered safely to those at greatest risk for HIV-1 infection and prevented as what is coined a chemical vaccine. The project is a collaboration with the Clinton Health Access Initiative whose support will be focused on drug manufacture. Testing and development of the medicines will be done by our scientific staff. 

Neuroimmunology of Disease Training Program
MPI:  Gendelman, H.E. and Monaghan, D.
NIH/NINDS T32 NS105594
This program will provide unique research training experiences in infectious, developmental, and degenerative nervous system diseases. By combining cross-disciplinary team-mentored training in the immune-brain axis, the next generation of neuroscientists will be able to incorporate multidisciplinary approaches into novel research paradigms. This is done to better understand disease processes and develop state-of-the-art diagnostic and therapeutic interventions. The University of Nebraska Medical Center is well positioned to offer this unique cross-disciplinary educational experience.

Chronic HIV infection and Aging in NeuroAIDS (CHAIN) Center
MPI: Buch, S and Fox, H.; Therapeutics Core Leader: Gendelman, H. E.
NIH/NIMH P30 MH062261
This is a Center grant to provide Administrative and Core Support for scientists investigating NeuroAIDS.

Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1
PI: Gendelman, H.E.
NIH/NIMH R01MH115860-01
In this proposal we seek to eradicate the human immunodeficiency virus (HIV) from its central nervous system and peripheral reservoirs. Dual humanized brain and immune system mice were created to reflect the complex neuroimmune communication networks seen in human disease. These mice will be used to assess brain viral reservoirs during combination antiretroviral therapy (cART) and gene delivery of a CRISPR/Cas9 for final viral excision. HIV elimination will be determined after cessation of cART and elimination of viral rebound.

Parkinson's Technology
PI: Gendelman, H.E.
Moderna Therapeutics
Improve the delivery of an immune transformative agent by engagement of a liposomal delivery system for RNA rather than protein in the treatment of Parkinson's disease.

Prodrug Formulations Create Sustained Release Antiretrovirals
MPI: Gendelman, H.E./Edagwa, B.
NIH/NIA 1 R01AI145542
This award will be used to convert short acting antiretroviral drugs into long-acting slow effective release ART (LASER ART) with potent and selective activities against the human immunodeficiency virus type one (HIV-1). The LASER ART chemically modified to create hydrophobic and lipophilic drug crystals in order to extend the drug dosing intervals from once/day to once/6 months. The generation of decorated drug nanocrystals can be boosted by a second medicine that protects the first from cell destruction and thereby serves to improve reservoir delivery to body tissue sites where HIV-1 grows such as the lymph nodes and gut.

HIV Theranostics
PI: Gendelman, H.E.
NIH/NIMH R01MH121402
This award is to convert nucleoside reverse transcriptase and an integrase inhibitor(s) into long-acting slow effective release antiretroviral nanocrystals with improved safety and efficacy against human immunodeficiency virus infection.  Prodrug nanocrystals are lipophilic and stabilized by biocompatible surfactants. The formulations are being developed with the potential to extend drug-dosing intervals up to once every six months.

top of page


Techniques used in laboratory

top of page


Personnel

Aditya Bade, PhD
Instructor 

Aditya Bade, PhD

Rajashree Chakraborty
Graduate Research Assistant
IGPBS Biochemistry and Molecular Biology
Co-mentored with Dr. Benson Edagwa

Rajashree Chakraborty

Prasanta Dash, PhD
Assistant Professor 

Prasanta_Dash_2015

Srijanee Das
Graduate Research Assistant
IGPBS Immunology, Pathology, and Infectious Disease 
Co-mentored with Dr. Benson Edagwa

Srijanee Das

Suyash Deodhar
Graduate Research Assistant
IGPBS Neuroscience
Co-mentored with Dr. Benson Edagwa

Suyash Deodhar

Benson Edagwa, PhD
Associate Professor 

Benson Edagwa, PhD

Theresa Grutel
Administrative Associate

Theresa Grutel


Mahmudul Hasan
Graduate Research Assistant
Pharmaceutical Sciences 

Mahmudul Hasan

Farhana Islam
Graduate Research Assistant
IGPBS Biochemistry and Molecular Biology

Farhana_Islam.png Bhavesh Kevadiya, PhD
Assistant Professor
Bhavesh_Kevadiya.jpeg
Yaman Lu
Research Technologist 
Yaman Lu

 

Jatinkumar Pravi Machhi, PhD
Instructor

Jatinkumar Machhi, PhD

JoEllyn McMillan, PhD
Associate Professor 

 

JoEllyn McMillan

Mai Mostafa
Graduate Research Assistant
Pharmaceutical Sciences
Co-mentored with Dr. Lee Mosley

Mai-Mostafa.png

Krista Namminga
Research Technician II

Krista Namminga

Mohammad Ullah Nayan
Graduate Research Assistant
IGPBS Neuroscience
Co-mentored with Dr. Benson Edagwa

Mohammad_Ullah_Nayan

Kate Olson-Johnson, PhD
Instructor

Kate Olson, PhD

Milankumar Patel
Graduate Research Assistant
Medical Sciences Interdepartmental Area (MSIA) Patient-Oriented Research (POR)

Milankumar Patel

Farah Shahjin
Graduate Research Assistant
IGPBS Neuroscience

Farah Shahjin

Bhagya Laxmi Dyavar Shetty
Research Technologist, II

Bhagya Laxmi Dyavar Shetty

Brady Sillman, PhD
Instructor

Brady_Sillman_2021_square.jpg

Emiko Waight
Research Technologist I

Emiko_Waight_2021_square.jpg

 

Pravin Yeapuri
Graduate Research Assistant
Department of Pharaceutical Sciences
No_photo.png Chen Zhang
Graduate Research Assistant
IGPBS Neuroscience 
Chen-Zhang-reduced-square.jpg

Dr. Gendelman's home page

Dr. Gendelman's biographical information
Top of page